 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Celltrion Group shares fell en masse on the 27th. Investor sentiment has been dampened by the mention that it may be difficult for Humira biosimilar Yuflyma to be listed in the U.S. insurance. Celltrion has refuted that it is not true.
Celltrion shares closed at 150,800 won, down 8.66% from the previous day. Celltrion Healthcare and Celltrion Pharmaceutical also closed down 8.05% and 5.89%, respectively.
Behind the drop in Celltrion's three brothers' stock prices was the issue of U.S. insurance listing of Humara biosimilar Yuflyma. According to Pierce Healthcare of the U.S. on the 23rd (local time), Optum Rx, an insurance drug management company (PBM), decided to add Humira biosimilars and confirmed Amgen, Sandoz and BI.
Celltrion Healthcare claims that whether it is unclear whether it is listed on the insurance is not true. "In the market for Humira, the top three PBMs are responsible for 80% of the prescription and is divided into private insurance and public insurance," the company said. "It is a contract with Formula, which covers about 10% of the 21% of the Humira market held by Optum Rx, and we will continue to consult with other PBMs."
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
